GlassScriptPhysician profile
Simone A Fearon
NPI 1255522801
$5,927.27
in general payments reported to CMS, 2019-2025
24 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,571 · 2021: $157 · 2022: $814 · 2023: $987 · 2024: $41.07 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,473.51 | 2019-2023 | Cardiomems |
| Bracco Diagnostics INC. | $319.37 | 2025 | |
| Novartis Pharmaceuticals Corporation | $307.38 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $244.04 | 2022-2023 | Xarelto |
| Lantheus Medical Imaging, INC. | $185.63 | 2021-2024 | Definity |
| Boston Scientific Corporation | $179.38 | 2019-2025 | Watchman Flx |
| Amgen INC. | $144.14 | 2021-2023 | Repatha |
| Pfizer INC. | $136.19 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $131.45 | 2022-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.89 | 2022-2023 | Jardiance |
| Philips North America LLC | $117.33 | 2019-2025 | Epiq Cvx |
| Merck Sharp & Dohme LLC | $74.45 | 2022-2023 | Verquvo |
| Edwards Lifesciences Corporation | $73.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $71.57 | 2022-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $60.34 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $59.70 | 2022-2023 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $46.52 | 2022 | |
| Medtronic, INC. | $36.49 | 2021-2023 | Corevalve Evolut R |
| Scpharmaceuticals INC. | $31.54 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.37 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $23.81 | 2022 | |
| Getinge USA Sales, LLC | $23.63 | 2023 | Sensation 7fr. 34cc Iab |
| Irhythm Technologies, INC. | $22.26 | 2023 | Zio Xt Patch |
| Kiniksa Pharmaceuticals, LTD. | $17.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simone Fearon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.